BH3-mimetic drugs offer potential to treat Legionella infections
8 March 2016 | By Victoria White
Turning off BCL-XL with BH3-mimetic drugs killed Legionella-infected cells, allowing the infection to be cleared from the body...
List view / Grid view
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
8 March 2016 | By Victoria White
Turning off BCL-XL with BH3-mimetic drugs killed Legionella-infected cells, allowing the infection to be cleared from the body...
3 March 2016 | By Victoria White
Scientists at the University of Brighton have shown that bacteriophage can treat infections caused by Proteus mirabilis and prevent catheter blockage...
22 February 2016 | By Katie Sadler
Pherecydes Pharma has announced the appointment of Guy-Charles Fanneau de La Horie, MBA as its new Chief Executive Officer.
Bacterial resistance to antibiotics is on the rise and a return to the ‘pre-antibiotic’ era has become a frightening possibility. Various factors are responsible for this situation: the overuse of antibiotics in human medicine and animal husbandry, insufficient public funding for research into fundamental bacteriology including resistance mechanisms, and a…
16 February 2016 | By Victoria White
MGB Biopharma and the University of Strathclyde are to extend their existing collaboration to develop novel MGB anti-infectives...
12 February 2016 | By Victoria White
The latest report from the Review on Antimicrobial Resistance says that vaccines and other alternatives can play a vital role in tackling the rise of drug-resistant infections...
Antibody-based targeting of vascular endothelial growth factor (VEGF) is a highly successful and widely-used clinical treatment for angiogenesis-related diseases. Currently, bevacizumab (Avastin; Genentech) and ranibizumab (Lucentis; Genentech/Roche) are the leading antibody drugs for targeting VEGF...
28 January 2016 | By Victoria White, Digital Content Producer, Drug Target Review
2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
13 January 2016 | By Victoria White
NIAID has awarded $5 million in funding for 24 research projects to help address the growing health threat of antibiotic resistance...
11 January 2016 | By Victoria White
The collaboration will focus on the development of drugs targeting important human oncogenes, including RAS, and new antibiotics targeting Gram-negative bacteria...
14 December 2015 | By Victoria White
A new study outlines a way of using antibiotic resistance to find chemicals capable of stopping amyloid formation in amyloid diseases such as Parkinson’s, Alzheimer’s and type II diabetes...
11 December 2015 | By Victoria White
The study will look at the safety and tolerability of PnuBioVax for three different dosages against the bacterial pathogen Streptococcus pneumoniae...
7 December 2015 | By Victoria White
The €100m ENABLE project aims to identify at least three antibacterial lead molecules with promising antibacterial activity, two antibacterial clinical candidate molecules and to enter at least one compound into preclinical and Phase 1 clinical studies...
26 November 2015 | By Victoria White
Scientists from the University of Toronto have switched off, one by one, almost 18,000 genes - 90% of the entire human genome - to find the genes that are essential for cell survival...